Further steps in the development of pharmacoeconomics, outcomes research, and health technology assessment in central and Eastern Europe, Western Asia, and Africa

Value in Health Regional Issues

Volumn 2, Issue 2, 2013, Pages 169-170

  Boncz, Imre ^a   Kaló, Zoltán ^b   Mohamed Ibrahim, Mohamed Izham B ^c   Greenberg, Dan ^d  

^a UNIVERSITY OF PÉCS   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c Qatar University ^*  (Qatar)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; ASIA; CENTRAL EUROPE; COST BENEFIT ANALYSIS; EASTERN EUROPE; EDITORIAL; EUROPE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH IMPACT ASSESSMENT; LIFE EXPECTANCY; OUTCOMES RESEARCH; PHARMACOECONOMICS; POLITICAL SYSTEM; PRIORITY JOURNAL; PUBLICATION; WESTERN ASIA;

EID: 84884135194     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2013.07.007     Document Type: Editorial

References (13)

1. Khonputsa P., Veerman L.J., Bertram M., et al. Generalized cost-effectiveness analysis of pharmaceutical interventions for primary prevention of cardiovascular disease in Thailand. Value Health Regional 2012, 1:15-22.
2. Kim B.R.M., Lee T.J., Lee H.J., et al. Cost-effectiveness of sertindole among atypical antipsychotics in the treatment of schizophrenia in South Korea. Value Health Regional 2012, 1:59-65.
3. Janusz CB, Jauregui B, Sinha A, et al. Performing country-led economic evaluations to inform immunization policy: ProVac experiences in Latin America and the Caribbean. Value Health Regional 2012;1:248-53.
4. Augustovski F, Rojas JAD, Ferraz MB, et al. Status update of the reimbursement review environment in the public sector across four Latin American countries. Value Health Regional 2012;1:223-7.
5. World Health Organization. World Health Statistics 2013. Geneva, Switzerland: World Health Organization, 2013.
6. Vokó Z., Nagyjánosi L., Margitai B., et al. Modeling cost-effectiveness of cervical cancer screening in Hungary. Value Health 2012, 15:39-45.
7. Shmueli A., Fraifeld S., Peretz T., et al. Cost effectiveness of baseline low-dose CT screening for lung cancer: the Israeli experience. Value Health 2013, 16:922-931.
8. Inotai A., Pékli M., Jóna G., et al. Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology. BMC Health Serv Res 2012, 12:332.
9. Abuzar A., Yassir A.H., Mohamed Izham M.I. Do Saudi community pharmacists know how to use MDIs?. J Pharm Prac Res 2012, 42:77.
10. Greenberg D., Siebzehner M., Pliskin J.S. The process of updating the National List of Health Services in Israel: is it legitimate? is it fair?. Int J Technol Assess Health Care 2009, 25:255-271.
11. Abdulkareem M.A.S., Mohamed Izham M.I., Ahmed A.R. The quality of prescriptions with antibiotics in Yemen. J Clin Diagnostic Res 2011, 5:808-812.
12. Boncz I., Brodszky V., Péntek M., et al. The disease burden of colorectal cancer in Hungary. Eur J Health Econ 2010, 10(S1):S35-S40.
13. Boncz I., Sebestyen A. Financial deficits in the health services of the UK and Hungary. Lancet 2006, 368:917-918.